MARKET

TERN

TERN

Terns Pharmaceuticals, Inc.
NASDAQ
4.145
+0.085
+2.09%
Opening 14:41 02/18 EST
OPEN
4.110
PREV CLOSE
4.060
HIGH
4.265
LOW
4.105
VOLUME
746.66K
TURNOVER
--
52 WEEK HIGH
11.40
52 WEEK LOW
4.030
MARKET CAP
352.07M
P/E (TTM)
-3.5172
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TERN last week (0210-0214)?
Weekly Report · 1d ago
Weekly Report: what happened at TERN last week (0203-0207)?
Weekly Report · 02/10 09:16
Terns Pharma: I Don't See The Positioning
Seeking Alpha · 02/08 09:44
Terns Pharmaceuticals CFO Resignation and Leadership Transition
TipRanks · 02/06 22:29
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Simply Wall St · 02/06 10:06
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Barchart · 02/05 15:05
Novartis CEO discusses search for obesity deals with WSJ
TipRanks · 02/04 16:00
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/03 21:05
More
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Webull offers Terns Pharmaceuticals Inc stock information, including NASDAQ: TERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TERN stock methods without spending real money on the virtual paper trading platform.